We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major therapeutic areas. RPG will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing better clinical development services.

The acquisition underscores a strategic step forward to expand WuXi’s clinical research capabilities in the United States and around the world, further strengthening our integrated R&D capability platform. This is an important milestone in our mission towards building the most comprehensive and integrated enabling platform to help our global partners bring better medicines faster to patients around the world.